New drug MK-8294 tested in patients with advanced cancers
NCT ID NCT07030712
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and researchers will monitor side effects and how well the tumors respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Houston Methodist Hospital ( Site 0103)
RECRUITINGHouston, Texas, 77030, United States
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0300)
RECRUITINGAmsterdam, North Holland, 1066 CX, Netherlands
-
Northwestern University ( Site 0101)
RECRUITINGChicago, Illinois, 60611, United States
-
Radboudumc ( Site 0301)
RECRUITINGNijmegen, Gelderland, 6525 GA, Netherlands
-
Rambam Health Care Campus ( Site 0201)
RECRUITINGHaifa, 3109601, Israel
-
Sheba Medical Center ( Site 0200)
RECRUITINGRamat Gan, 5265601, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.